NLRP3 and metabolic dysfunction-associated steatotic liver disease: Oral administration of SFN prevented hepatic steatosis in a high-fat diet-induced mouse NAFLD model, and the effect was mediated by inhibition of the lipid-induced NLRP3 inflammasome in hepatocytes by SFN (Yang et al. 2016).